ART12.11
Undisclosed
Key Facts
About Artelo Biosciences
Artelo Biosciences is a clinical-stage biotech focused on developing therapeutics that modulate lipid-signaling pathways, with a primary mission to improve treatments for cancer and related conditions. Its most advanced asset, ART27.13, has demonstrated promising Phase 2 efficacy in reversing weight loss and improving lean body mass in cancer anorexia-cachexia syndrome (CACS), positioning it as a potential first-in-class therapy. The company's strategy involves advancing this lead program while leveraging its platform to develop additional assets targeting the endocannabinoid system and fatty acid binding proteins. Artelo operates as a public, micro-cap company, navigating the high-risk, high-reward landscape of early-stage drug development.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |
| Therapeutic Programs | Agathos Biologics | Pre-clinical |